Revenue guidance for FY 2025 has been revised to reflect organic growth of -1% to +1%. The lab solutions segment is expected to range from low single-digit decline to flat growth, while bioscience ...

The study by Li et al. provides fundamental findings supported by convincing evidence that they defined cellular reprogramming of androgen receptor in neuroendocrine prostate cancer (NEPC). The ...

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...

Previously, the phase 3 VISION study showed efficacy of 177 Lu-PSMA-617 in patients with mCRPC who were previously treated with at least one androgen receptor pathway inhibitor and 1-2 taxane-based ...

The organization just got $10 million from the Ascendium Education Group to help build a statewide network of apprenticeship pathways to reach more people. President and CEO Lindsay Blumer said it ...